Sensorion
Developing life-transforming therapies for patients with inner ear disorders involving vertigo and hearing loss.
Launch date
Employees
Market cap
CAD401m
Enterprise valuation
CAD350m (Public information from Sep 2024)
Share price
€0.93 ALSEN.PA
Company register number 512757725
Montpellier Occitanie (HQ)
Financials
Estimates*
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.9m | 3.3m | 4.0m | 4.7m | 13.9m | 14.2m | 7.6m |
| % growth | (24 %) | 74 % | 21 % | 18 % | 193 % | 2 % | (47 %) |
| EBITDA | (8.5m) | (14.6m) | (22.3m) | (21.3m) | (23.7m) | (36.7m) | (40.1m) |
| % EBITDA margin | (446 %) | (439 %) | (554 %) | (450 %) | (171 %) | (259 %) | (531 %) |
| Profit | (9.0m) | (15.1m) | (23.2m) | (22.1m) | (23.9m) | (37.1m) | (39.9m) |
| % profit margin | (469 %) | (454 %) | (577 %) | (465 %) | (172 %) | (262 %) | (528 %) |
| EV / revenue | 60.1x | 32.2x | 1.8x | 16.9x | 9.4x | 12.0x | 27.1x |
| EV / EBITDA | -13.5x | -7.3x | -0.3x | -3.8x | -5.5x | -4.6x | -5.1x |
| R&D budget | 7.7m | 14.6m | 22.9m | 22.8m | - | - | - |
| R&D % of revenue | 401 % | 438 % | 570 % | 480 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €800k | Seed | |
€270k | Grant | ||
€4.0m | Series A | ||
| N/A | €8.3m Valuation: €23.1m | IPO | |
* | €8.6m | Post IPO Equity | |
| N/A | €20.0m | Post IPO Debt | |
* | €18.1m | Post IPO Equity | |
€31.2m Valuation: €131m 51.8x EV/LTM Revenues -12.5x EV/LTM EBITDA | Private Placement VC | ||
€5.0m | Post IPO Equity | ||
* | €35.0m | Private Placement VC | |
* | €50.5m | Private Placement VC | |
* | €15.5m | Post IPO Equity | |
| Total Funding | CAD183m | ||
Related Content
Recent News about Sensorion
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.